Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis
Status:
Terminated
Trial end date:
2019-04-08
Target enrollment:
Participant gender:
Summary
This study is to compare the two medications Denosumab and Zoledronic Acid For Patients With
Beta Thalassemia Major Induced Osteoporosis. Patients with B-thalassemia major induce
osteoporosis will undergo baseline assessment of the bone densitometry by Dual-energy X-ray
absorptiometry scan as a standard of care by the radiology department, then a blood test for
bone specific Alkaline phosphatase and type-1 Carboxy Telopeptide will be measured by the
chemistry lab.
Patients with B-Thalassemia Major induced osteoporosis, who are 18 years of age or more and
willing to participate in the study will be enrolled after consenting by the primary
investigator in hematology outpatient clinic. Patients with osteoporosis will receive one of
the two medications, at the end of the year Dual-energy X-ray absorptiometry scan will be
done to compare the response of the two medications. The potential risks include the
drug-related side effects